Literature DB >> 19448136

Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry.

Sophie C Turfus1, Mark C Parkin, David A Cowan, John M Halket, Norman W Smith, Robin A Braithwaite, Simon P Elliot, Glyn B Steventon, Andrew T Kicman.   

Abstract

In vitro biosynthesis using pooled human liver microsomes was applied to help identify in vivo metabolites of ketamine by liquid chromatography (LC)-tandem mass spectrometry. Microsomal synthesis produced dehydronorketamine, seven structural isomers of hydroxynorketamine, and at least five structural isomers of hydroxyketamine. To aid identification, stable isotopes of the metabolites were also produced from tetra-deuterated isotopes of ketamine or norketamine as substrates. Five metabolites (three hydroxynorketamine and two hydroxyketamine isomers) gave chromatographically resolved components with product ion spectra indicating the presence of a phenolic group, with phenolic metabolites being further substantiated by selective liquid-liquid extraction after adjustments to the pH. Two glucuronide conjugates of hydroxynorketamine were also identified. Analysis by LC-coupled ion cyclotron resonance mass spectrometry gave unique masses in accordance with the predicted elemental composition. The metabolites, including the phenols, were subsequently confirmed to be present in urine of subjects after oral ketamine administration, as facilitated by the addition of deuterated metabolites generated from the in vitro biosynthesis. To our knowledge, phenolic metabolites of ketamine, including an intact glucuronide conjugate, are here reported for the first time. The use of biologically synthesized deuterated material as an internal chromatographic and mass spectrometric marker is a viable approach to aid in the identification of metabolites. Metabolites that have particular diagnostic value can be selected as candidates for chemical synthesis of standards.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19448136      PMCID: PMC2712439          DOI: 10.1124/dmd.108.026328

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  31 in total

1.  Pharmacokinetics of ketamine in man.

Authors:  J Wieber; R Gugler; J H Hengstmann; H J Dengler
Journal:  Anaesthesist       Date:  1975-06       Impact factor: 1.041

2.  Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes.

Authors:  Y Yanagihara; S Kariya; M Ohtani; K Uchino; T Aoyama; Y Yamamura; T Iga
Journal:  Drug Metab Dispos       Date:  2001-06       Impact factor: 3.922

Review 3.  Biotransformation and disposition of ketamine.

Authors:  T Chang; A J Glazko
Journal:  Int Anesthesiol Clin       Date:  1974

4.  On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects.

Authors:  M L Cohen; A J Trevor
Journal:  J Pharmacol Exp Ther       Date:  1974-05       Impact factor: 4.030

Review 5.  The use of stable isotopes in pharmacological research.

Authors:  T A Baillie
Journal:  Pharmacol Rev       Date:  1981-06       Impact factor: 25.468

6.  Stability of ketamine and its metabolites norketamine and dehydronorketamine in human biological samples.

Authors:  Y Hijazi; M Bolon; R Boulieu
Journal:  Clin Chem       Date:  2001-09       Impact factor: 8.327

7.  Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury.

Authors:  Y Hijazi; C Bodonian; M Bolon; F Salord; R Boulieu
Journal:  Br J Anaesth       Date:  2003-02       Impact factor: 9.166

8.  Detection of acid-labile conjugates of ketamine and its metabolites in urine samples collected from pub participants.

Authors:  Huei R Lin; Ahai C Lua
Journal:  J Anal Toxicol       Date:  2004-04       Impact factor: 3.367

9.  Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations.

Authors:  J D Adams; T A Baillie; A J Trevor; N Castagnoli
Journal:  Biomed Mass Spectrom       Date:  1981-11

10.  Metabolic alpha-hydroxylation of N-nitrosomorpholine and 3,3,5,5-tetradeutero-N-nitrosomorpholine in the F344 rat.

Authors:  S S Hecht; R Young
Journal:  Cancer Res       Date:  1981-12       Impact factor: 12.701

View more
  14 in total

1.  A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome.

Authors:  Ruin Moaddel; Swarajya Lakshmi Vattem Venkata; Mary J Tanga; James E Bupp; Carol E Green; Lalitha Iyer; Anna Furimsky; Michael E Goldberg; Marc C Torjman; Irving W Wainer
Journal:  Talanta       Date:  2010-08-13       Impact factor: 6.057

Review 2.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 3.  Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.

Authors:  Jaclyn N Highland; Panos Zanos; Lace M Riggs; Polymnia Georgiou; Sarah M Clark; Patrick J Morris; Ruin Moaddel; Craig J Thomas; Carlos A Zarate; Edna F R Pereira; Todd D Gould
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

4.  Stereoselective and regiospecific hydroxylation of ketamine and norketamine.

Authors:  Zeruesenay Desta; Ruin Moaddel; Evan T Ogburn; Cong Xu; Anuradha Ramamoorthy; Swarajya Lakshmi Vattem Venkata; Mitesh Sanghvi; Michael E Goldberg; Marc C Torjman; Irving W Wainer
Journal:  Xenobiotica       Date:  2012-05-21       Impact factor: 1.908

5.  Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression.

Authors:  Xiaochen Zhao; Swarajya Lakshmi Vattem Venkata; Ruin Moaddel; Dave A Luckenbaugh; Nancy E Brutsche; Lobna Ibrahim; Carlos A Zarate; Donald E Mager; Irving W Wainer
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

6.  Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration.

Authors:  Ingeborg Noppers; Erik Olofsen; Marieke Niesters; Leon Aarts; René Mooren; Albert Dahan; Evan Kharasch; Elise Sarton
Journal:  Anesthesiology       Date:  2011-06       Impact factor: 7.892

7.  Enantioselective pharmacokinetics of (R)- and (S)-ketamine after a 5-day infusion in patients with complex regional pain syndrome.

Authors:  Michael E Goldberg; Marc C Torjman; Robert J Schwartzman; Donald E Mager; Irving W Wainer
Journal:  Chirality       Date:  2010-08-27       Impact factor: 2.437

8.  Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors.

Authors:  Ruin Moaddel; Galia Abdrakhmanova; Joanna Kozak; Krzysztof Jozwiak; Lawrence Toll; Lucita Jimenez; Avraham Rosenberg; Thao Tran; Yingxian Xiao; Carlos A Zarate; Irving W Wainer
Journal:  Eur J Pharmacol       Date:  2012-11-23       Impact factor: 4.432

9.  The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats.

Authors:  Ruin Moaddel; Mitesh Sanghvi; Katina Sourou Sylvestre Dossou; Anuradha Ramamoorthy; Carol Green; James Bupp; Robert Swezey; Kathleen O'Loughlin; Irving W Wainer
Journal:  Pharmacol Res Perspect       Date:  2015-06-22

10.  Urine metabolomics in rats after administration of ketamine.

Authors:  Congcong Wen; Meiling Zhang; Jianshe Ma; Lufeng Hu; Xianqin Wang; Guanyang Lin
Journal:  Drug Des Devel Ther       Date:  2015-02-03       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.